In the current WHO list of bacterial priority pathogens (WHO BPPL 2024), the World Health Organisation classifies carbapenem-resistant Pseudomonas aeruginosa bacteria as a high-priority pathogen, which means there is an urgent need for new anti-infectives to combat this problematic bacterium. To address this need, the PAFAP project has brought together a [...]

Bacterial infections are one of the most severe complications in patients with decompensated liver cirrhosis. The immune system of this patient group is weakened due to a complex dysfunction of the immune system (cirrhosis-associated immune dysfunction, CAID). The cause of the immune system dysfunction is mainly due to the fact [...]

The SARS-CoV-2 pandemic and other epidemics in recent decades have highlighted the need to develop effective measures to combat emerging infectious diseases in a timely manner. For most emerging viral pathogens, no vaccines or antiviral drugs are yet available. Since it is difficult to predict which virus or viral variants [...]

Helicobacter pylori, Campylobacter jejuni, and Campylobacter coli are among the most widespread bacterial pathogens and responsible for annually hundreds of thousands of cases of diarrhoea, intestinal inflammation, gastric ulcers and stomach cancer worldwide. The research group led by Christine Josenhans at the Ludwig-Maximilians-Universität München (LMU) is developing pathoblockers [...]

The challenge of antibiotic drug development today is the discovery and optimisation of novel bioactive compounds that do not show cross-resistances with clinically applied antibiotics, ideally due to a novel mode of action (MoA) which adresses unexploited microbial targets. In the case of chelocardin, this antibiotic substance was identified several [...]